• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".

作者信息

Koh Kwang Kon

机构信息

Department of Cardiovascular Medicine, Heart Center, Gachon University, Gil Medical Center, Incheon, Korea. Gachon Cardiovascular Research Institute, Incheon, Korea.

出版信息

Circulation. 2019 Jan 15;139(3):416-417. doi: 10.1161/CIRCULATIONAHA.118.037209.

DOI:10.1161/CIRCULATIONAHA.118.037209
PMID:30640544
Abstract
摘要

相似文献

1
Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".Koh就《卡格列净与2型糖尿病患者的心力衰竭：CANVAS项目（卡格列净心血管评估研究）结果》一文所写的信
Circulation. 2019 Jan 15;139(3):416-417. doi: 10.1161/CIRCULATIONAHA.118.037209.
2
Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".菲格特里等人对关于“《卡格列净与2型糖尿病患者的心力衰竭：CANVAS项目（卡格列净心血管评估研究）的结果》”一文的信函的回应。
Circulation. 2019 Jan 15;139(3):418-419. doi: 10.1161/CIRCULATIONAHA.118.038477.
3
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.CANVAS 项目：卡格列净对降低 2 型糖尿病患者心血管风险的影响。
Cardiovasc Diabetol. 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2.
4
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.卡格列净与 2 型糖尿病患者的肾脏结局：CANVAS 项目随机临床试验的结果。
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
5
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.卡格列净与 2 型糖尿病患者骨折风险：CANVAS 计划研究结果。
Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.
6
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).卡格列净用于心血管事件的一级和二级预防：来自 CANVAS 项目（卡格列净心血管评估研究）的结果。
Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.
7
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.CANVAS和EMPA-REG心血管结局试验中2型糖尿病（T2DM）患者报告的结局相关成本的经济模型。
J Med Econ. 2019 Mar;22(3):280-287. doi: 10.1080/13696998.2018.1562817. Epub 2019 Jan 11.
8
[Outcome studies on SGLT-2 inhibitors].[钠-葡萄糖协同转运蛋白2抑制剂的疗效研究]
Internist (Berl). 2019 Sep;60(9):903-911. doi: 10.1007/s00108-019-0656-x.
9
Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.糖尿病：钠-葡萄糖协同转运蛋白2抑制剂对心血管和肾脏的益处：来自CANVAS研究的见解
Nat Rev Nephrol. 2017 Sep;13(9):517-518. doi: 10.1038/nrneph.2017.113. Epub 2017 Aug 7.
10
How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂如何预防心力衰竭？
JACC Heart Fail. 2020 Jan;8(1):67-69. doi: 10.1016/j.jchf.2019.11.009.